No withdrawals, so far, from Norway’s cancer tender as a result of MFN

Rare-disease treatment access sparks Danish debate

Innovative agreements are gaining further traction in Denmark

TLV’s new pricing and reimbursement framework is now in force.

Lif urges faster, broader access decisions for rare-disease treatments

These are the winners and losers in Norway’s cancer drug tender

CHMP recommends 12 medicines at September meeting

Enhertu becomes available in the UK for HER2-low advanced breast cancer

University of Oslo aims for first Norwegian opportunity cost estimate in 2027

Medicinrådet issues two green lights and two red lights